A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations

Simply Wall St.04-09 16:25

A short seller report from Culper Research accused ADMA Biologics (ADMA) of channel stuffing and inflating revenue growth, followed by multiple law firms launching securities law investigations and a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626907806?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-09 16:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626907806","market":"nz","top_or_hot":-1,"title":"A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations","media":"Simply Wall St.","content":"<div>\n<p>A short seller report from Culper Research accused ADMA Biologics (ADMA) of channel stuffing and inflating revenue growth, followed by multiple law firms launching securities law investigations and a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-short-seller-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At ADMA Biologics (ADMA) Valuation After Short Seller Allegations And Legal Investigations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 16:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-short-seller-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A short seller report from Culper Research accused ADMA Biologics (ADMA) of channel stuffing and inflating revenue growth, followed by multiple law firms launching securities law investigations and a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-short-seller-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-short-seller-a","article_id":"2626907806","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/a-look-at-adma-biologics-adma-valuation-after-short-seller-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626907806","pubTimestamp":1775723119,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"A short seller report from Culper Research accused ADMA Biologics (ADMA) of channel stuffing and inflating revenue growth, followed by multiple law firms launching securities law investigations and a sharp one day share price drop.\nSee our latest analysis for ADMA Biologics.\nAgainst this backdrop of short seller allegations and legal investigations, ADMA Biologics’ recent 1-day share price return of 6.16% and 7-day share price return of 7.90% follow a much weaker 30-day share price return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc","BK4139":"生物科技"},"translate_title":"卖空者指控和法律调查后ADMA Biologics(ADMA)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1.5},"content_text":"A short seller report from Culper Research accused ADMA Biologics (ADMA) of channel stuffing and inflating revenue growth, followed by multiple law firms launching securities law investigations and a sharp one day share price drop. See our latest analysis for ADMA Biologics. Against this backdrop of short seller allegations and legal investigations, ADMA Biologics’ recent 1-day share price return of 6.16% and 7-day share price return of 7.90% follow a much weaker 30-day share price return of 37.82% and year to date share price return of 45.02%. The 3 year total shareholder return is more than 3x despite a 1 year total shareholder return decline of 49.30%, suggesting long term holders have seen substantial gains but short term momentum has faded. If this kind of volatility has you looking beyond a single biotech name, it could be a moment to scan for other opportunities through 34 healthcare AI stocks With allegations, legal probes, and a sharp pullback already on the table, today’s US$9.83 share price and very large discount to analyst targets raise the key question: is ADMA Biologics now undervalued, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 53% Undervalued According to the most followed valuation narrative, ADMA Biologics’ fair value of $20.93 sits well above the recent $9.83 share price, creating a wide gap for investors to assess.  I assume ADMA can generate 1 BUSD in revenues by 2029 (S29) with FCF margin 35% (FCF29 = 350 MUSD) and net profit margin of 30% (E29 = 300 MUSD) To be conservative let me assume lower multiples for ADMA in 2029 than CSL currently has, although ADMA may still have a higher growth rate than CSL currently has  Read the complete narrative. The valuation story is built on strong revenue expansion, high margins, and a future earnings multiple that resembles a mature leader rather than an early stage biotech. It raises questions about which specific growth and profitability assumptions support that US$20 fair value estimate and how sensitive the narrative might be to even small changes in those inputs. Result: Fair Value of $20.93 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on ADMA delivering on aggressive revenue, margin and yield assumptions, while short seller claims or legal outcomes could still weigh on sentiment and valuation multiples. Find out about the key risks to this ADMA Biologics narrative. Next Steps With sentiment divided between sharp concerns and a strong undervaluation narrative, it can be useful to act promptly and evaluate the key data points yourself using 3 key rewards and 2 important warning signs Looking for more investment ideas? If ADMA’s story has you thinking bigger, do not sit on the sidelines. While others scan for alternatives, broaden your watchlist now using these targeted stock idea lists.  Target potential mispricings early by reviewing 64 high quality undervalued stocks that combine attractive pricing with solid underlying fundamentals. Prioritize resilience by focusing on 72 resilient stocks with low risk scores that score well on financial strength and business stability. Get ahead of the crowd by tracking the screener containing 24 high quality undiscovered gems before they attract wider attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626907806","isCrawlerRequest":true}